Finally, the clinical usage of SeV is limited, including a phase I clinical trial with a SeV vector expressing the human fibroblast growth factor-2 (FGF-2) gene to treat peripheral arterial disease [18]. This evidence concerns the gene FGF2 and peripheral arterial disease.